Industry Research Reports

Home > Reports > Medical Care > Viral Vectors Gene Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Viral Vectors Gene Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Medical Care

Published Date: 2025-01-13

Pages: 109 Pages

Report ld: 3503439

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Viral Vectors Gene Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Viral Vectors Gene Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vectors Gene Therapy by region & country, by Type, and by Application.

The Viral Vectors Gene Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors Gene Therapy.

MARKET SEGMENTATION

By Company

Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Retro Viral Vectors
Adeno-associated Virus Vectors
Other Viral Vectors

Segment by Application

In Vivo
Ex Vivo

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Viral Vectors Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Viral Vectors Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Viral Vectors Gene Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Viral Vectors Gene Therapy Product Introduction

1.2 Global Viral Vectors Gene Therapy Market Size Forecast (2020-2031)

1.3 Viral Vectors Gene Therapy Market Trends & Drivers

1.3.1 Viral Vectors Gene Therapy Industry Trends

1.3.2 Viral Vectors Gene Therapy Market Drivers & Opportunity

1.3.3 Viral Vectors Gene Therapy Market Challenges

1.3.4 Viral Vectors Gene Therapy Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Viral Vectors Gene Therapy Players Revenue Ranking (2024)

2.2 Global Viral Vectors Gene Therapy Revenue by Company (2020-2025)

2.3 Key Companies Viral Vectors Gene Therapy Manufacturing Base Distribution and Headquarters

2.4 Key Companies Viral Vectors Gene Therapy Product Offered

2.5 Key Companies Time to Begin Mass Production of Viral Vectors Gene Therapy

2.6 Viral Vectors Gene Therapy Market Competitive Analysis

2.6.1 Viral Vectors Gene Therapy Market Concentration Rate (2020-2025)

2.6.2 Global 5 and 10 Largest Companies by Viral Vectors Gene Therapy Revenue in 2024

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors Gene Therapy as of 2024)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Retro Viral Vectors

3.1.2 Adeno-associated Virus Vectors

3.1.3 Other Viral Vectors

3.2 Global Viral Vectors Gene Therapy Sales Value by Type

3.2.1 Global Viral Vectors Gene Therapy Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Viral Vectors Gene Therapy Sales Value, by Type (2020-2031)

3.2.3 Global Viral Vectors Gene Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 In Vivo

4.1.2 Ex Vivo

4.2 Global Viral Vectors Gene Therapy Sales Value by Application

4.2.1 Global Viral Vectors Gene Therapy Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Viral Vectors Gene Therapy Sales Value, by Application (2020-2031)

4.2.3 Global Viral Vectors Gene Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

5.1 Global Viral Vectors Gene Therapy Sales Value by Region

5.1.1 Global Viral Vectors Gene Therapy Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Viral Vectors Gene Therapy Sales Value by Region (2020-2025)

5.1.3 Global Viral Vectors Gene Therapy Sales Value by Region (2026-2031)

5.1.4 Global Viral Vectors Gene Therapy Sales Value by Region (%), (2020-2031)

5.2 North America

5.2.1 North America Viral Vectors Gene Therapy Sales Value, 2020-2031

5.2.2 North America Viral Vectors Gene Therapy Sales Value by Country (%), 2024 VS 2031

5.3 Europe

5.3.1 Europe Viral Vectors Gene Therapy Sales Value, 2020-2031

5.3.2 Europe Viral Vectors Gene Therapy Sales Value by Country (%), 2024 VS 2031

5.4 Asia Pacific

5.4.1 Asia Pacific Viral Vectors Gene Therapy Sales Value, 2020-2031

5.4.2 Asia Pacific Viral Vectors Gene Therapy Sales Value by Region (%), 2024 VS 2031

5.5 South America

5.5.1 South America Viral Vectors Gene Therapy Sales Value, 2020-2031

5.5.2 South America Viral Vectors Gene Therapy Sales Value by Country (%), 2024 VS 2031

5.6 Middle East & Africa

5.6.1 Middle East & Africa Viral Vectors Gene Therapy Sales Value, 2020-2031

5.6.2 Middle East & Africa Viral Vectors Gene Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Viral Vectors Gene Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Viral Vectors Gene Therapy Sales Value, 2020-2031

6.3 United States

6.3.1 United States Viral Vectors Gene Therapy Sales Value, 2020-2031

6.3.2 United States Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Viral Vectors Gene Therapy Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Viral Vectors Gene Therapy Sales Value, 2020-2031

6.4.2 Europe Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Viral Vectors Gene Therapy Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Viral Vectors Gene Therapy Sales Value, 2020-2031

6.5.2 China Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

6.5.3 China Viral Vectors Gene Therapy Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Viral Vectors Gene Therapy Sales Value, 2020-2031

6.6.2 Japan Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Viral Vectors Gene Therapy Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Viral Vectors Gene Therapy Sales Value, 2020-2031

6.7.2 South Korea Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Viral Vectors Gene Therapy Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Viral Vectors Gene Therapy Sales Value, 2020-2031

6.8.2 Southeast Asia Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Viral Vectors Gene Therapy Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Viral Vectors Gene Therapy Sales Value, 2020-2031

6.9.2 India Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

6.9.3 India Viral Vectors Gene Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Amgen

7.1.1 Amgen Profile

7.1.2 Amgen Main Business

7.1.3 Amgen Viral Vectors Gene Therapy Products, Services and Solutions

7.1.4 Amgen Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.1.5 Amgen Recent Developments

7.2 Novartis

7.2.1 Novartis Profile

7.2.2 Novartis Main Business

7.2.3 Novartis Viral Vectors Gene Therapy Products, Services and Solutions

7.2.4 Novartis Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.2.5 Novartis Recent Developments

7.3 Orchard Therapeutics

7.3.1 Orchard Therapeutics Profile

7.3.2 Orchard Therapeutics Main Business

7.3.3 Orchard Therapeutics Viral Vectors Gene Therapy Products, Services and Solutions

7.3.4 Orchard Therapeutics Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.3.5 Orchard Therapeutics Recent Developments

7.4 Spark Therapeutics

7.4.1 Spark Therapeutics Profile

7.4.2 Spark Therapeutics Main Business

7.4.3 Spark Therapeutics Viral Vectors Gene Therapy Products, Services and Solutions

7.4.4 Spark Therapeutics Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.4.5 Spark Therapeutics Recent Developments

7.5 Agc Biologics

7.5.1 Agc Biologics Profile

7.5.2 Agc Biologics Main Business

7.5.3 Agc Biologics Viral Vectors Gene Therapy Products, Services and Solutions

7.5.4 Agc Biologics Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.5.5 Agc Biologics Recent Developments

7.6 Anges

7.6.1 Anges Profile

7.6.2 Anges Main Business

7.6.3 Anges Viral Vectors Gene Therapy Products, Services and Solutions

7.6.4 Anges Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.6.5 Anges Recent Developments

7.7 Bluebird Bio

7.7.1 Bluebird Bio Profile

7.7.2 Bluebird Bio Main Business

7.7.3 Bluebird Bio Viral Vectors Gene Therapy Products, Services and Solutions

7.7.4 Bluebird Bio Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.7.5 Bluebird Bio Recent Developments

7.8 Jazz Pharmaceuticals

7.8.1 Jazz Pharmaceuticals Profile

7.8.2 Jazz Pharmaceuticals Main Business

7.8.3 Jazz Pharmaceuticals Viral Vectors Gene Therapy Products, Services and Solutions

7.8.4 Jazz Pharmaceuticals Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.8.5 Jazz Pharmaceuticals Recent Developments

7.9 Dynavax Technologies

7.9.1 Dynavax Technologies Profile

7.9.2 Dynavax Technologies Main Business

7.9.3 Dynavax Technologies Viral Vectors Gene Therapy Products, Services and Solutions

7.9.4 Dynavax Technologies Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.9.5 Dynavax Technologies Recent Developments

7.10 Biogen

7.10.1 Biogen Profile

7.10.2 Biogen Main Business

7.10.3 Biogen Viral Vectors Gene Therapy Products, Services and Solutions

7.10.4 Biogen Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.10.5 Biogen Recent Developments

7.11 Sarepta Therapeutics

7.11.1 Sarepta Therapeutics Profile

7.11.2 Sarepta Therapeutics Main Business

7.11.3 Sarepta Therapeutics Viral Vectors Gene Therapy Products, Services and Solutions

7.11.4 Sarepta Therapeutics Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.11.5 Sarepta Therapeutics Recent Developments

7.12 Gilead Sciences

7.12.1 Gilead Sciences Profile

7.12.2 Gilead Sciences Main Business

7.12.3 Gilead Sciences Viral Vectors Gene Therapy Products, Services and Solutions

7.12.4 Gilead Sciences Viral Vectors Gene Therapy Revenue (US$ Million) & (2020-2025)

7.12.5 Gilead Sciences Recent Developments

8 Industry Chain Analysis

8.1 Viral Vectors Gene Therapy Industrial Chain

8.2 Viral Vectors Gene Therapy Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Viral Vectors Gene Therapy Sales Model

8.5.2 Sales Channel

8.5.3 Viral Vectors Gene Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Viral Vectors Gene Therapy Market Trends

Table 2. Viral Vectors Gene Therapy Market Drivers & Opportunity

Table 3. Viral Vectors Gene Therapy Market Challenges

Table 4. Viral Vectors Gene Therapy Market Restraints

Table 5. Global Viral Vectors Gene Therapy Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Viral Vectors Gene Therapy Revenue Market Share by Company (2020-2025)

Table 7. Key Companies Viral Vectors Gene Therapy Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Viral Vectors Gene Therapy Product Type

Table 9. Key Companies Time to Begin Mass Production of Viral Vectors Gene Therapy

Table 10. Global Viral Vectors Gene Therapy Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors Gene Therapy as of 2024)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Viral Vectors Gene Therapy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 14. Global Viral Vectors Gene Therapy Sales Value by Type (2020-2025) & (US$ Million)

Table 15. Global Viral Vectors Gene Therapy Sales Value by Type (2026-2031) & (US$ Million)

Table 16. Global Viral Vectors Gene Therapy Sales Market Share in Value by Type (2020-2025)

Table 17. Global Viral Vectors Gene Therapy Sales Market Share in Value by Type (2026-2031)

Table 18. Global Viral Vectors Gene Therapy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 19. Global Viral Vectors Gene Therapy Sales Value by Application (2020-2025) & (US$ Million)

Table 20. Global Viral Vectors Gene Therapy Sales Value by Application (2026-2031) & (US$ Million)

Table 21. Global Viral Vectors Gene Therapy Sales Market Share in Value by Application (2020-2025)

Table 22. Global Viral Vectors Gene Therapy Sales Market Share in Value by Application (2026-2031)

Table 23. Global Viral Vectors Gene Therapy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 24. Global Viral Vectors Gene Therapy Sales Value by Region (2020-2025) & (US$ Million)

Table 25. Global Viral Vectors Gene Therapy Sales Value by Region (2026-2031) & (US$ Million)

Table 26. Global Viral Vectors Gene Therapy Sales Value by Region (2020-2025) & (%)

Table 27. Global Viral Vectors Gene Therapy Sales Value by Region (2026-2031) & (%)

Table 28. Key Countries/Regions Viral Vectors Gene Therapy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 29. Key Countries/Regions Viral Vectors Gene Therapy Sales Value, (2020-2025) & (US$ Million)

Table 30. Key Countries/Regions Viral Vectors Gene Therapy Sales Value, (2026-2031) & (US$ Million)

Table 31. Amgen Basic Information List

Table 32. Amgen Description and Business Overview

Table 33. Amgen Viral Vectors Gene Therapy Products, Services and Solutions

Table 34. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Amgen (2020-2025)

Table 35. Amgen Recent Developments

Table 36. Novartis Basic Information List

Table 37. Novartis Description and Business Overview

Table 38. Novartis Viral Vectors Gene Therapy Products, Services and Solutions

Table 39. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Novartis (2020-2025)

Table 40. Novartis Recent Developments

Table 41. Orchard Therapeutics Basic Information List

Table 42. Orchard Therapeutics Description and Business Overview

Table 43. Orchard Therapeutics Viral Vectors Gene Therapy Products, Services and Solutions

Table 44. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Orchard Therapeutics (2020-2025)

Table 45. Orchard Therapeutics Recent Developments

Table 46. Spark Therapeutics Basic Information List

Table 47. Spark Therapeutics Description and Business Overview

Table 48. Spark Therapeutics Viral Vectors Gene Therapy Products, Services and Solutions

Table 49. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Spark Therapeutics (2020-2025)

Table 50. Spark Therapeutics Recent Developments

Table 51. Agc Biologics Basic Information List

Table 52. Agc Biologics Description and Business Overview

Table 53. Agc Biologics Viral Vectors Gene Therapy Products, Services and Solutions

Table 54. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Agc Biologics (2020-2025)

Table 55. Agc Biologics Recent Developments

Table 56. Anges Basic Information List

Table 57. Anges Description and Business Overview

Table 58. Anges Viral Vectors Gene Therapy Products, Services and Solutions

Table 59. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Anges (2020-2025)

Table 60. Anges Recent Developments

Table 61. Bluebird Bio Basic Information List

Table 62. Bluebird Bio Description and Business Overview

Table 63. Bluebird Bio Viral Vectors Gene Therapy Products, Services and Solutions

Table 64. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Bluebird Bio (2020-2025)

Table 65. Bluebird Bio Recent Developments

Table 66. Jazz Pharmaceuticals Basic Information List

Table 67. Jazz Pharmaceuticals Description and Business Overview

Table 68. Jazz Pharmaceuticals Viral Vectors Gene Therapy Products, Services and Solutions

Table 69. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Jazz Pharmaceuticals (2020-2025)

Table 70. Jazz Pharmaceuticals Recent Developments

Table 71. Dynavax Technologies Basic Information List

Table 72. Dynavax Technologies Description and Business Overview

Table 73. Dynavax Technologies Viral Vectors Gene Therapy Products, Services and Solutions

Table 74. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Dynavax Technologies (2020-2025)

Table 75. Dynavax Technologies Recent Developments

Table 76. Biogen Basic Information List

Table 77. Biogen Description and Business Overview

Table 78. Biogen Viral Vectors Gene Therapy Products, Services and Solutions

Table 79. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Biogen (2020-2025)

Table 80. Biogen Recent Developments

Table 81. Sarepta Therapeutics Basic Information List

Table 82. Sarepta Therapeutics Description and Business Overview

Table 83. Sarepta Therapeutics Viral Vectors Gene Therapy Products, Services and Solutions

Table 84. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Sarepta Therapeutics (2020-2025)

Table 85. Sarepta Therapeutics Recent Developments

Table 86. Gilead Sciences Basic Information List

Table 87. Gilead Sciences Description and Business Overview

Table 88. Gilead Sciences Viral Vectors Gene Therapy Products, Services and Solutions

Table 89. Revenue (US$ Million) in Viral Vectors Gene Therapy Business of Gilead Sciences (2020-2025)

Table 90. Gilead Sciences Recent Developments

Table 91. Key Raw Materials Lists

Table 92. Raw Materials Key Suppliers Lists

Table 93. Viral Vectors Gene Therapy Downstream Customers

Table 94. Viral Vectors Gene Therapy Distributors List

Table 95. Research Programs/Design for This Report

Table 96. Key Data Information from Secondary Sources

Table 97. Key Data Information from Primary Sources

Table 98. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Viral Vectors Gene Therapy Product Picture

Figure 2. Global Viral Vectors Gene Therapy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Viral Vectors Gene Therapy Sales Value (2020-2031) & (US$ Million)

Figure 4. Viral Vectors Gene Therapy Report Years Considered

Figure 5. Global Viral Vectors Gene Therapy Players Revenue Ranking (2024) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Viral Vectors Gene Therapy Revenue in 2024

Figure 7. Viral Vectors Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 8. Retro Viral Vectors Picture

Figure 9. Adeno-associated Virus Vectors Picture

Figure 10. Other Viral Vectors Picture

Figure 11. Global Viral Vectors Gene Therapy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 12. Global Viral Vectors Gene Therapy Sales Value Market Share by Type, 2024 & 2031

Figure 13. Product Picture of In Vivo

Figure 14. Product Picture of Ex Vivo

Figure 15. Global Viral Vectors Gene Therapy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 16. Global Viral Vectors Gene Therapy Sales Value Market Share by Application, 2024 & 2031

Figure 17. North America Viral Vectors Gene Therapy Sales Value (2020-2031) & (US$ Million)

Figure 18. North America Viral Vectors Gene Therapy Sales Value by Country (%), 2024 VS 2031

Figure 19. Europe Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 20. Europe Viral Vectors Gene Therapy Sales Value by Country (%), 2024 VS 2031

Figure 21. Asia Pacific Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 22. Asia Pacific Viral Vectors Gene Therapy Sales Value by Region (%), 2024 VS 2031

Figure 23. South America Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 24. South America Viral Vectors Gene Therapy Sales Value by Country (%), 2024 VS 2031

Figure 25. Middle East & Africa Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 26. Middle East & Africa Viral Vectors Gene Therapy Sales Value by Country (%), 2024 VS 2031

Figure 27. Key Countries/Regions Viral Vectors Gene Therapy Sales Value (%), (2020-2031)

Figure 28. United States Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 29. United States Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

Figure 30. United States Viral Vectors Gene Therapy Sales Value by Application (%), 2024 VS 2031

Figure 31. Europe Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 32. Europe Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

Figure 33. Europe Viral Vectors Gene Therapy Sales Value by Application (%), 2024 VS 2031

Figure 34. China Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 35. China Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

Figure 36. China Viral Vectors Gene Therapy Sales Value by Application (%), 2024 VS 2031

Figure 37. Japan Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 38. Japan Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

Figure 39. Japan Viral Vectors Gene Therapy Sales Value by Application (%), 2024 VS 2031

Figure 40. South Korea Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 41. South Korea Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

Figure 42. South Korea Viral Vectors Gene Therapy Sales Value by Application (%), 2024 VS 2031

Figure 43. Southeast Asia Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 44. Southeast Asia Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

Figure 45. Southeast Asia Viral Vectors Gene Therapy Sales Value by Application (%), 2024 VS 2031

Figure 46. India Viral Vectors Gene Therapy Sales Value, (2020-2031) & (US$ Million)

Figure 47. India Viral Vectors Gene Therapy Sales Value by Type (%), 2024 VS 2031

Figure 48. India Viral Vectors Gene Therapy Sales Value by Application (%), 2024 VS 2031

Figure 49. Viral Vectors Gene Therapy Industrial Chain

Figure 50. Viral Vectors Gene Therapy Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

Figure 54. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Viral Vectors Gene Therapy market? zhanKai

The top companies in the global Viral Vectors Gene Therapy market are Amgen、Novartis、Orchard Therapeutics.

Related Reports

Global Viral Vectors Gene Therapy Market Research Report 2025
The global market for Viral Vectors Gene Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-13
Pages: 84
USD 2900.00
(Single User License)
Global Viral Vectors Gene Therapy Market Insights, Forecast to 2030
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Published Date: 2024-04-10
Pages: 107
USD 4900.00
(Single User License)
Global Viral Vectors Gene Therapy Market Research Report 2024
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Published Date: 2024-01-17
Pages: 83
USD 2900.00
(Single User License)

Global Viral Vectors Gene Therapy Market Research Report 2025
The global market for Viral Vectors Gene Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-13
Pages: 84
USD 2900.00 (Single User License)
Global Viral Vectors Gene Therapy Market Insights, Forecast to 2030
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Published: 2024-04-10
Pages: 107
USD 4900.00 (Single User License)
Global Viral Vectors Gene Therapy Market Research Report 2024
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Published: 2024-01-17
Pages: 83
USD 2900.00 (Single User License)